Glaukos Announces Participation in Upcoming Investor Conferences
28 Mayo 2024 - 6:00AM
Business Wire
Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical
and medical technology company focused on novel therapies for the
treatment of glaucoma, corneal disorders and retinal diseases,
today announced that its management is scheduled to participate in
the following upcoming investor conferences:
- William Blair 44th Annual Growth Stock Conference on Wednesday,
June 5, 2024, at 1:40 p.m. ET in Chicago, IL
- Truist MedTech Conference on Tuesday, June 18, 2024, at 12:45
p.m. ET in Boston, MA
A live and archived webcast for these events, where applicable,
will be available in the Investors section of the Glaukos website
at http://investors.glaukos.com.
About Glaukos
Glaukos (www.glaukos.com) is an ophthalmic pharmaceutical and
medical technology company focused on developing and
commercializing novel therapies for the treatment of glaucoma,
corneal disorders and retinal diseases. Glaukos first developed
Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the
traditional glaucoma treatment paradigm, launching its first MIGS
device commercially in 2012, and continues to develop a portfolio
of technologically distinct and leverageable platforms to support
ongoing pharmaceutical and medical device innovations. Products or
product candidates for each of these platforms are designed to
advance the standard of care through better treatment options
across the areas of glaucoma, corneal disorders and retinal
diseases.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240528383262/en/
Chris Lewis Vice President, Investor Relations & Corporate
Affairs (949) 481-0510 clewis@glaukos.com
Glaukos (NYSE:GKOS)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Glaukos (NYSE:GKOS)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024